ABENEX takes majority stake in INLOG

Private equity firm Abenex, utilizing its dedicated Small Caps fund Abenex Croissance, has successfully completed the acquisition of healthcare software publisher Inlog from US-based industrial group Haemonetics. Executed on September 21, 2020, this corporate carve-out ends a 12-year integration within the American conglomerate, with Inlog's management team reinvesting alongside the new financial sponsor. The buyout is supported by a senior debt facility co-arranged by Banque Populaire Val de France and Caisse d’Epargne Rhône-Alpes. This transaction represents the fourth platform investment for the Abenex Croissance fund. For Abenex, the investment is designed to provide the necessary resources to institutionalize the internationally active software publisher and accelerate its operational growth. Leveraging this new financial backing, Inlog will expedite the development of new functional features for its CE-marked medical device software, which provides mission-critical blood product traceability and laboratory management solutions. Furthermore, the company aims to solidify its strategic partnerships with its base of over 250 French and European clients, which prominently includes university hospitals (C.H.U.) and the French Blood Establishment (EFS).